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There are multiple, distinct B-cell populations in human beings and other animals such as
mice. In the latter species, there is a well-characterized subset of B-cells known as B1 cells,
which are enriched in peripheral sites such as the peritoneal cavity but are rare in the blood.
B1 cells can be further subdivided into B1a and B1b subsets. There may be additional B1
subsets, though it is unclear if these are distinct populations or stages in the developmen-
tal process to become mature B1a and B1b cells. A limitation in understanding B1 subsets
is the relative paucity of specific surface markers. In contrast to mice, the existence of B1
cells in human beings is controversial and more studies are needed to investigate the nature
of these enigmatic cells. Examples of B1b antigens include pneumococcal polysaccharide
and the Vi antigen from Salmonella Typhi, both used routinely as vaccines in human beings
and experimental antigens such as haptenated-Ficoll. In addition to inducing classical T-
dependent responses some proteins are B1b antigens and can induce T-independent (TI)
immunity, examples include factor H binding protein from Borrelia hermsii and porins from
Salmonella. Therefore, B1b antigens can be proteinaceous or non-proteinaceous, induce
TI responses, memory, and immunity, they exist in a diverse range of pathogenic bacteria,
and a single species can contain multiple B1b antigens. An unexpected benefit to study-
ing B1b cells is that they appear to have a propensity to recognize protective antigens in
bacteria. This suggests that studying B1b cells may be rewarding for vaccine design as
immunoprophylactic and immunotherapeutic interventions become more important due
to the decreasing efficacy of small molecule antimicrobials.
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THE IMPORTANCE OF B-CELLS IN VACCINATION
B-cells carry a unique signature through the expression of a
distinct surface immunoglobulin receptor. Under favorable cir-
cumstances, if the cognate antigen is engaged and appropriate
secondary signals are received, the B-cell can differentiate into a
plasma cell and secrete antibody through at least two pathways
(1, 2). Depending upon the specificity, antibody can help prevent
infections from establishing and protecting against a number of
infectious diseases. B-cells can have additional activities during
infection, which are not necessarily related to antibody produc-
tion, where they provide signals through contact-dependent and
-independent mechanisms as seen during experimental infections
with the helminth Nippostrongylus brasiliensis (3). Such antibody-
independent activities of B-cells are clearly important in infectious
and non-infectious diseases (4–6). Thus, B-cells are important
modulators of the host response and the growing and extending
interest in the effector activities of B-cells is a welcome expansion
of our understanding of the activities of this cell type.
Nevertheless, it is the antibody-mediated effector functions
of B-cells that are estimated to save >2 million lives yearly (7).
Antibody is behind the elimination of smallpox and the drastic
reductions in the prevalence of measles, polio, diphtheria, tetanus,
and a plethora of other infections for which vaccines exist, bring-
ing tremendous economic and social benefits (8). Moreover, once
infections have been encountered and natural immunity acquired,
then the levels of antibody often correlate to the levels of pro-
tection against reinfection (9). Vaccines and antibody typically
protect at the first encounter with a pathogen, usually before clin-
ical signs are apparent and when bacterial numbers are at their
lowest. In contrast, antibiotics are used when bacterial burdens
are toward their peak and when clinical signs are more prominent.
This game of numbers is probably a key reason why antimicrobial
resistance is more common than resistance to a vaccine. As we head
toward an era where increased resistance means existing antimi-
crobials will be less efficacious, there will be an increasing reliance
on antibody-mediated mechanisms to protect us. To achieve this
requires an efficient way to identify protective antigens. This is an
important concept as separating out which antigens are protective
from those antigens which are not is a timely, complex, and costly
process (10). Therefore, understanding how to efficiently identify
protective antigenic targets on pathogens will be a valuable tool
for the future control of infection. We propose that understanding
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the nature and targets of B1 cells, particularly B1b cells, is one
such route for this. In this review, we discuss elements associ-
ated with B1 cells and infection, with a major emphasis on the
relationship between bacterial antigens and B1b cells. This is in
part to maintain a focus in the review, but also because other
elements of B1 cell biology, particularly B1a cell biology, such as
their development, role in housekeeping functions, and in diseases,
such as autoimmunity, have been elegantly reviewed elsewhere in
detail (11–36).
THE ROLE OF ANTIBODY IN INFECTIONS AND RESPONSES
TO VACCINATION
Virtually, all vaccines work through the induction of antibody. The
key point here is that, in general, antibody needs to be pre-existing
at the time of pathogen encounter indicating the importance of
inducing a persisting plasma-cell response to maintain this pro-
tective blanket of antibody. It is clearly desirable to induce B-cell
memory to complement these activities and to augment antibody
levels after antigen re-encounter, but responses to vaccination with
T-independent (TI) antigens such as purified capsular polysac-
charides show that robust memory is not essential for vaccines
to work (37). Antibody induced to T-dependent (TD) antigens,
such as proteins, is induced in two waves. Initially, after antigen
encounter extrafollicular (EF) IgM is induced, which is typically
of modest affinity as at the earliest time after antigen encounter,
it is not derived from germinal centers (GCs; see below). Slightly
later, the first IgG is detected, which increases in affinity with time
as the GC makes a greater contribution (1, 2). Nevertheless, IgM
is normally present with IgG to make a significant contribution to
protection (38–42). In mice, the isotype of IgG induced can reflect
the nature of the immune response. IgG3 is the dominant switched
isotype after TI antigens, whereas IgG1 and IgG2a reflect T helper
(Th) 2 and Th1 responses, respectively (38). In vivo, the predomi-
nant IgG isotype to a single antigen can vary depending upon the
antigenic context in which it is encountered by the immune system
(43). A relationship between the direction of Th responses and the
direction of IgG switching is less clear in human beings, although
some responses are more associated with certain IgG isotypes, for
instance IgG2 and IgG4 antibodies are commonly found to LPS O
chain and helminths, respectively (44, 45).
Multiple experimental models of infection show that IgM is
critical for much of the short- and long-term protection afforded
after natural infection and that the functional roles of IgM and
IgG are likely to be synergistic (40, 46). The high avidity of pen-
tameric IgM means that it is efficient at activating complement,
whereas not all IgG isotypes are equally efficient at doing this
(47). In response to most infections or proteinaceous vaccines,
IgG titers will rise over many weeks, whereas IgM titers typically
remain steady or fall. High affinity IgG is not induced by purified
capsular polysaccharides (48).
For instance, the value of IgG has been demonstrated in studies
using antibody generated during a natural non-typhoidal Sal-
monella infection or by an experimental protein vaccine against
this infection that can induce TI and TD responses (46, 49).
In these studies, the consistent observation was that IgG could
account for up to 95% of the protection observed in wild-type
(WT) mice, although surprisingly the additional benefit of IgG
was not necessarily related to it being of high affinity. However,
the role of IgG in the absence of IgM was not assessed in these
studies. An additional consideration is that cell-free, antibody-
dependent, complement-mediated bactericidal killing in mice may
not be equally active against all infections. This is notable in Sal-
monella infections, where mouse serum is not effective at killing
the organisms in bactericidal assays in vitro as human serum is,
and so the true value of IgM and antibody per se may be under-
represented in murine systems (50). A further consideration is
that the amount of antibody induced to a single antigen can affect
outcome. Individuals with HIV/AIDS have a known increased sus-
ceptibility to invasive non-typhoidal Salmonella infections (51).
The reason for this was recently attributed to elevated titers of
inhibitory IgG to LPS and removal of this antibody enabled bac-
terial killing by the remaining non-inhibitory antibodies (52). A
similar observation has been made in patients with bronchiecta-
sis and a Pseudomonas aeruginosa infection (53). A proportion of
these patients have markedly elevated titers of IgG2 to LPS O chain
that inhibits cell-free or cell-dependent killing of bacteria. There-
fore, efficient protection after infection or vaccination requires
antibody to selective targets, present in the right amount and of
the right isotype.
THE DEVELOPMENT OF ANTIBODY RESPONSES TO
T-DEPENDENT AND INDEPENDENT ANTIGENS
There are classically three types of antigens (54–56). Some, such
as LPS, can act as TI type I antigens, which induce specific and
non-specific antibody responses through direct stimulation of the
B-cell. A second class of antigens is TI type II antigens. Antigens
that fall into this group include purified capsular polysaccharide
vaccines such as those generated from pneumococcus and the
experimental antigen, haptenated Ficoll. Typical haptens include
4-hydroxy-3-nitrophenyl acetyl (NP) and variations of this such
as DNP and TNP. A feature of TI–II antigens is that within a
single molecule, there are multiple repeats of the same epitope.
This means that there is spatial co-localization of the same epitope
and when a B-cell encounters the antigen, then multiple surface
B-cell receptors are engaged in parallel (57). This drives a strong
signaling response within the cell and abrogates the necessity for
T-cell support to generate an antibody response. The third class
of antigens is TD antigens, which are generally proteins. This is
then processed and presented to T-cells via MHCII to enable their
recruitment into the response. Conjugation of a TI–II antigen
to a protein carrier can convert it into a TD antigen, a process
that typically requires physical linkage (58, 59). The consequences
of T-cell involvement in the generation of antibody responses
are dramatic, since it ultimately results in the induction of pro-
ductive GCs and the generation of greater amounts of switched
antibody of a higher affinity and the generation of robust long
lived and memory B-cell responses. Furthermore, conjugating a
TI antigen to a protein carrier enables responses to capsular poly-
saccharide vaccines to be induced in certain groups, such as infants,
in whom responses would otherwise be refractory (60, 61). The
concept of classes of antibody responses has been the focus of
recent discussion (62). This has led to the development of the idea
of a TI–III response, which displays unique features, as well as
sharing some with other types of B-cell responses. The distinct
Frontiers in Immunology | B Cell Biology October 2014 | Volume 5 | Article 535 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cunningham et al. B1b cells and responses to infection and vaccines
features of the TI–III response focus on the support provided
by additional bone marrow-derived cells including neutrophils,
monocytes, mast cells, and basophils and are induced after infec-
tion with bloodborne or gut bacteria. They result in the production
of EF antibody and show a marked dependence on TLR signaling
for their development.
In mice, responses to model TI-2 and TD alum-precipitated
antigens such as NP-chicken gamma globulin or ovalbumin, the
kinetics of the immune response has been well characterized for
both primary and recall responses and below is a short synop-
sis based on this non-exhaustive list of references (1, 2, 63–69)
(Figure 1). It is likely most of the core features of this response
reflect what happens in human beings. After antigen encounter,
dendritic cells within the T-zone present and prime T-cells within
the first 24 h to enable their rapid differentiation to T follicular
helper (Tfh) cells. The dendritic cell subset involved in Tfh prim-
ing, Ig switching, and other T effector functions may not always
be the same since different subsets can provide these functions in
different sites concurrently. For instance, we have found that after
flagellin immunization CD103+ dendritic cells prime for IgA and
IgG in the mesenteric lymph node but not the spleen, and that
after Salmonella infection monocyte-derived dendritic cells help
prime for IFNγ-expression in T-cells but not IgG2a responses (70,
71). In parallel, B-cells that have engaged antigen interact with
primed Tfh cells also within the T-zone. Depending upon the sig-
nals received, B-cells can essentially have one of the three fates.
They can die, or while still in the T-zone start to differentiate and
proliferate. A proportion of these cells will migrate to the follicles
and with the adequate recruitment of Tfh cells start to form GCs.
Other B-cells will migrate to EF sites such as the red pulp of the
spleen or the medulla of lymph nodes to generate plasmablasts and
ultimately plasma cells. The kinetics are important for this process
and so by around 5 days after immunization, an initial wave of
short-lived IgM and IgG (predominantly IgG1 in mice) plasma
cells is readily detectable in EF sites. These peak by around day 7
before gradually falling over the coming days (72). With slightly
delayed kinetics, GCs form within the follicles and contribute the
majority of plasma cells by a week or so after immunization. The
key points that are applicable to the current discussion are that
after proteinaceous molecules there is a parallel development of
EF and GC responses, and that there is a robust EF switched IgG
response.
What is less appreciated is that the process for the generation of
responses to TI–II antigens is similar, but with accelerated kinet-
ics. Thus, after antigen encounter, B-cells still migrate through the
T-zone and start to proliferate in this site. Furthermore, some B-
cells migrate to the follicles to form GCs that abort around the
fourth day after immunization as they lack T-cell help to main-
tain them. Robust EF plasma-cell responses develop with a rapid
expansion of the plasmablast population and the immunoglobu-
lin isotypes most commonly detected are IgM and (in mice) IgG3.
There are two major consequences of failing to induce Tfh and GC,
mainly the longevity of the antibody response is shorter than that
commonly seen to protein antigens, and upon reencountering the
same antigen, an accelerated and augmented secondary response
is absent. This is a significant clinical problem since hyporespon-
siveness to a second immunization with a TI–II vaccine is often
FIGURE 1 |The development of antibody responses. Specific antibody
responses develop in secondary lymphoid tissues. B-cells responding to
T-dependent and T-independent antigens migrate through the T-zone before
producing antibody through the germinal center (GC) or extrafollicular (EF)
pathway. Tfh cell – T follicular helper.
seen. Thus, the mechanics of TD and TI antibody responses show
many key similarities.
THE DISTINCT FLAVORS OF B-CELL SUBSETS
In human beings and mice, there are multiple B-cell subsets,
including follicular B-cells and marginal zone (MZ) B-cells, as well
as transitional B-cells (17, 31, 73–77). Follicular and MZ B-cells
are known as B2 cells. MZ B-cells contain naïve and antigen-
experienced B-cells. Follicular B-cells in both species express IgM,
IgD and are CD21int/lo and CD23hi. The level of diversity in B-cell
receptor usage is greatest in follicular B-cells and accounts for most
of the enormous antibody diversity seen in B-cells. Their produc-
tive engagement in immune responses shows a clear dependence
on T-cells. MZ B-cells also share some similarities between mice
and human beings in terms of phenotype with both subsets being
IgM+, IgDlo/−, B220hi, CD21hi, and CD23lo. Neither B-cell subset
has the capacity to self-renew. There are differences between fol-
licular and MZ B-cells. These differences include the sites where
they reside, the more limited antigen repertoire recognized by MZ
B-cells, the immaturity of the MZ B-cell compartment after birth,
and finally, the capacity of MZ cells to respond to TI–II antigens.
These latter two points make the responsiveness of MZ B-cells
of significant clinical interest as TI vaccines have poor or negli-
gible efficacy in infants, which correlates with limited MZ B-cell
responses.
In mice, there are a number of additional B-cell subsets that are
recognized and these come under the umbrella term of B1 cells
(17, 22, 23, 26, 28, 31, 33). They are most associated with some
serosal sites such as the peritoneal cavity, although they can also
be detected in secondary lymphoid tissues and so are probably
more widespread than currently appreciated (78, 79). A key fea-
ture that distinguishes B1 subsets from B2 subsets is their capacity
to self-renew. Thus, transfer of B1 populations into lymphopenic
mice will result in their expansion over a period of weeks. This
means that it is possible to make B1 chimeric mice by transferring
peritoneal cells into a Rag-deficient mouse [e.g., Ref. (80)]. In the
steady state in the peritoneal cavity of a WT mouse, about 50% of
B-cells are B1 cells, and we find there is an approximate ratio of B1a
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cells to B1b cells of 2:1 (46, 81). A factor that complicates the study
of B1 cells is their more elusive phenotype. They express CD19,
low levels of IgD but relatively high levels of IgM. They can express
CD43 and CD9, are negative or low expressers for other markers
such as CD21 and CD23, and are mostly intermediate for B220 (27,
31, 82–84). In the spleen, many of their characteristics are similar
to transitional B-cells when at a transitional T1 stage. Identifica-
tion of B1a cells is substantially aided by their modest expression
of CD5, although in mice expressing CD5 is not necessarily exclu-
sive to B1a cells (85). Another marker closely associated with B1
cells is CD11b, but the frequency of B-cells expressing CD11b
can be variable; for instance, during some infections, it alters from
that seen during steady-state conditions (46). It is unclear whether
the differences in CD11b expression mark distinct B1 subsets or
reflect differing developmental stages (86–88). Nonetheless, these
factors make examining B1 cells more complicated, particularly in
secondary lymphoid tissues, and the often necessary reliance on
CD11b as a positive marker, though understandable, is likely to
mean their true numbers are underestimated.
EVIDENCE FOR B1 CELLS IN HUMAN BEINGS
In human beings, the identification of B1 cells has proven to be
a contentious issue (89–94). Part of the reason for this relates
to the difficulty in accessing sites such as the peritoneal cavity,
where B1 cells are enriched in mice. Nonetheless, currently, there
is limited evidence for an exact replication of the murine phe-
notype for B1 cells in human beings, particularly for B1a cells
(89, 91, 95, 96). One report has identified a rare population of
B-cells in patients with chronic variable immunodeficiency dis-
ease (97) and cells in other non-human primates (NHP) share
common B1b markers (98). B-cells in human fetal cord blood and
adult blood with a CD20+CD27+CD43+CD70- phenotype, but
with a variable expression of CD5, CD86, IgM, and IgD have been
identified as human B1 cells (89). The definition of these cells is
not solely based on surface markers as these cells also had other
properties associated with B1 responses. These include (i) the abil-
ity to spontaneously secrete IgM antibody to antigens associated
with B1 responses such as phosphorylcholine, a known target of
B1a-derived antibody in mice and (ii) the ability to readily inter-
act and prime T-cells. Interestingly, the probability of a human
B1 cell having either or both properties correlates to its expres-
sion of CD11b. Spontaneous IgM secretion is more associated
with CD11b− cells and T-cell modulating activity associated with
CD11b+ human B1 cells. Nevertheless, others have suggested that
CD27+CD43+CD70- B-cells may reflect a pre-plasmablast differ-
entiation state of cells present in the blood (93). It is tempting
to speculate how cumulative exposure to antigen may influence
the phenotype and frequency of B1 cells in different species since
B1 cells are more readily detectable in animals kept in controlled
environmental conditions. Therefore, currently, there is not a uni-
versally accepted definition for B1 cells in human beings as there
is for mice.
MICE CONTAIN MULTIPLE B1 SUBSETS
B1 cells can have phagocytic and antigen-presenting functions,
secrete cytokines to modulate the host and produce antibody,
with these properties not necessarily mutually exclusive within
individual cells (32, 99–101). Most work on B1 cells in mice has
focused on B1a cells, and their activities have been well reviewed by
a number of authors (see above). B1a cells express CD5 and, at least
in the steady state, are the dominant B1 subset in the peritoneal
cavity. They play a major role in maintaining host immunolog-
ical tone and homeostasis, but also make striking contributions
to the control of infections, such as influenza (15, 31, 102, 103).
What is striking about the role of B1a response to influenza is
that they contribute antibody through two pathways. The first is
through the production of natural antibody, which is generated
independent of the presence of cognate antigen. The second is
the generation of antibody during infection. Influenza infection
results in the accumulation of B1a cells to sites of infection and
their production of antibody specific to the pathogen. B1a cells
are able to generate IgM and IgA antibodies of modest affinity
that can be poly-reactive. Features of the B1a response are atypical
since it does not necessarily require the differentiation of B1a cells
into CD138-expressing plasma cells or the loss of B1a cell mark-
ers, and the majority of the B1a antibody induced is not specific to
influenza (104). This suggests a robust early and innate, if “blind”
antibody response, which functions to limit infection. While this
may simply be a “panic” response to a pathogen, it is also possible
that these cells also modulate immunity through phagocytic or
contact-dependent mechanisms.
The reported ability of B1a cells to secrete antibody after anti-
gen exposure, but without differentiation into plasma cells, raises
questions regarding the nature of antibody-secreting cells. This has
only been addressed in any detail for CD5+B1a cells, and is also an
area where reports do not necessarily converge. Based on in vitro,
ex vivo, and adoptive transfer studies, Rothstein and colleagues
have shown that antibody-secreting B1a cells in the peritoneal cav-
ity show limited expression of genes associated with plasma cells,
such as blimp-1 and CD138 (105). Furthermore, IRF4-deficient
peritoneal B1 cells can still secrete IgM, whereas splenic B1 cells
do not (106). Nevertheless, experiments using Blimp-1 reporter
mice failed to support these findings, although Blimp-1-deficient
mice retain the capacity to generate some immunoglobulin (107,
108). The differences in these studies may reflect the different
approaches taken or other factors. What is lacking is a detailed
comparison between plasma cells generated from B-cells of dif-
ferent origins that compare more than the antibody isotype they
produce or antigens they initially responded to, although this is
clearly a technical challenge.
B1b CELLS MAKE IMPORTANT CONTRIBUTIONS TO
PROTECTIVE IMMUNITY IN MICE
Much of the work examining the activities of B1a cells have focused
on their role in autoimmunity, while their roles in controlling
infection are less studied. B1a cells do not necessarily function in
isolation and, for instance, they can collaborate with B1b cells to
combat pneumococcal infections (80). Despite sharing many phe-
notypic features with B1a cells, such as the generation of natural
antibody to self-antigens (109), there are key differences between
B1a and B1b cells. There is evidence that each of these cell types
has a different developmental pathway and infection may increase
a progenitor population that has the potential to generate progeny
with a B1a-like phenotype (26–28, 30, 31, 33, 110–116). Another
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difference between B1a and B1b cells is that the latter tend to
exhibit a greater level of junctional diversity compared to B1a
cells suggesting a broader repertoire of antigens is recognized by
these cells, although this may be a more complex picture than pre-
viously envisaged (117–120). This then leads to a key question.
What antigens are recognized by B1b cells and are they clinically
relevant?
The first studies showing a potential clinical benefit of B1b
responses came from experiments using a murine model of relaps-
ing fever caused by the spirochete Borrelia hermsii (121, 122). This
bacterial infection in mice results in a pronounced bacteremia,
with bacterial numbers reaching >106–7 bacteria/ml blood, but
there is much less colonization of tissues by bacteria (123). A key
reason for this is the high degree of antigenic variation in certain
bacterial surface proteins (124). The infection relapses because
antibody develops to the dominant clone and as this is controlled
it enables the outgrowth of an antigenically distinct minor clone,
which goes on to cause another episode of fever. This can occur
multiple times, but typically each further round of bacteremia
is less severe than the one that preceded it. This suggests there
are protective antigens present that are unrelated to the variable
proteins and that the antibody response to these protective anti-
gens develops at a slower rate, due to potential reasons such as
antigen density or epitope availability. IgG can contribute to pro-
tection in this model but an absolute requirement for IgM has been
demonstrated (121–123). A role for B1b cells in protection against
B. hermsii was identified after infection of a range of genetically
altered mice (IL7−/−mice that are deficient in follicular B-cells),
splenectomized mice, and B-cell chimeric mice (121). Protection
was TI and reinfection of T-cell-deficient mice revealed that a
TI memory response was induced. Significantly, B1b chimeras
generated by transfer of B1b cells from convalescing mice into
Rag1-deficient hosts were more efficient at controlling infection
than equivalent chimeras generated using naïve B1b cells. This
finding of TI memory was reproduced in a separate model involv-
ing immunization with a polysaccharide antigen from Enterobacter
cloacae (125).
The unequivocal demonstration of a role for B1b cells in con-
trolling this infection raised questions regarding which antigen
was the target for this protective antibody. The obvious candi-
dates were the variable surface proteins from this pathogen, which
contribute to immune evasion, but this turned out not to be the
case. The target of the protective B1b antibody was a conserved
protein, the Factor H binding protein (fHbp), and the response to
this protein could develop in the absence of T-cells (126). Anti-
body to fHbp accumulates slowly with time and protection is only
achieved when levels of antibody to this antigen reaches a certain
level. This is sufficient to explain why each round of bacteremia
tends to be less severe than the one before. This is an important
finding and the concept it identifies has far reaching implications
for understanding protective immunity during natural infection
and for vaccinology. It means that targeting cell wall localized
immunodominant antigens is not necessarily required to gener-
ate immunity to different strains of the same organism. There are
manifold forms of fHbp produced by different bacterial genera and
these show significant variability at the protein level. This protein
is of interest to vaccinologists as it is one of the protective antigens
included in the Bexsero vaccine used against group B meningo-
coccus (127). Alugupalli and colleagues extended their findings
on fHbp from B. hermsii by generating mice with a humanized
immune system, so that all B-cells are derived from human progen-
itors (128). They showed these chimeras generated IgM antibody
to B. hermsii and to fHbp and that protection was dependent upon
B-cells. Although not formally shown, the antibody response in
these chimeras is likely to have been induced in a TI manner. This
is a landmark study since it demonstrates that human B-cells are
capable of generating anti-protein antibody responses in a manner
that resembles the process in mice.
Parallels can be observed between B1b cell responses in mice
and the B-cell response in other species to TI–II antigens, such as
capsular polysaccharides (78, 80). Classically, splenic MZ B-cells
are associated with the generation of antibody to such antigens, in
part because of the poor responses to capsular polysaccharide vac-
cines observed in asplenic adults and infants, who lack a mature
MZ B-cell compartment (74, 129). Nevertheless, mice deficient
in MZ B-cells can still make robust responses to TI–II antigens
(78, 130) so this does not negate the potential for B1b cells to
be involved in such responses. Also, B1b cells are detected in the
spleen after immunization with TI–II antigens and they can con-
tribute directly or through interactions with MZ B-cells (131, 132).
Although B1b cells can recognize haptenated Ficoll, the antigen
itself is not a natural antigen and it is typically absent from the
environment meaning that in the absence of immunization, ani-
mals are naïve to it. This has been exploited to identify the presence
of cells that phenotypically and functionally resemble B1 (both B1a
and B1b cells) in NHP (African green monkeys and cynomolgus
monkeys) (98). NHP B1 cells have a similar phenotype to cells in
mice and are CD11bhi forward scatter hi, CD21lo/− and CD19hi
and can upregulate CD27 upon antigen encounter. Like B1b cells,
in mice, they respond to TNP-Ficoll and produce IgM and IgG but
little IgA.
In an earlier pivotal study, Haas and colleagues demonstrated
that capsular polysaccharide from Streptococcus pneumoniae is
a B1b antigen and that B1b-derived antibody was sufficient to
protect against infection (80). Purified pneumococcal polysaccha-
ride is currently used as a vaccine in human beings against these
infections and such responses can be long lived (133, 134). The
response in B-cells also differs depending whether the vaccine is
conjugated or not (135). Additional studies using α-1,3 dextran
from the Gram-negative bacterium E. cloacae have identified B1b
cells as the principal reservoir of memory to bacterial polysaccha-
ride antigens (125). Indeed, B1b cells maintain the potential to
respond to pneumococcal polysaccharide throughout life (136),
with the mechanisms underlying the responsiveness of B1b cells
under active investigation (137). Therefore, identifying targets of
B1b cells may help in developing strategies to improve vaccination
against pneumococcus in the elderly, who are disproportionately
susceptible to these infections and in whom vaccination with
pneumovax has not had a dramatic effect on the incidence of
infection (138). It is likely that the number of infections where
B1b responses are important will expand. For instance, putative
evidence suggests that the characteristic response of the organism
Ehrlichia muris at least in part involves B1b cells (40, 139). Col-
lectively, studies such as those highlighted above show that B1b
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antigens are present in a plethora of bacterial genera of major
clinical importance and that these antigens can be key targets of
protective immunity.
SALMONELLA INFECTION AS A MODEL TO STUDY B1b CELLS
In murine systems, B1b cells can make a significant contri-
bution to protection. Our own work has examined the B-cell
response in the Gram-negative bacterium Salmonella enterica
serovar Typhimurium (49). Clearance of primary S. Typhimurium
infections in mice requires an intact and persisting CD4 T-cell
response regulated by the transcription factor T-bet (140–144).
Antibody can protect against secondary infection or after immu-
nization (46, 81, 145, 146). We came to study S. Typhimurium
indirectly as a development of our use of model antigens such as
ovalbumin and the bacterial TLR5 ligand flagellin (43, 147). Using
these antigens, we could show how altering the context in which an
antigen was encountered could significantly alter the T- and B-cell
response to it. Through immunohistological examination of the
splenic plasma-cell response after systemic S. Typhimurium infec-
tion, we noted that the response was highly atypical (Figure 2).
In particular, we noted that the bacterium induced a rapid EF
plasmablast response (49). On day 3 after S. Typhimurium, the
majority of IgM plasmablasts in the red pulp were in cell cycle,
and their numbers had already increased >10-fold. In parallel,
on day 3, there was also a 3–4-fold increase in IgG2a-switched
plasmablast numbers, rising to around 20-fold higher by day 4,
when most IgG2a cells are in cell cycle. In contrast to EF responses
after immunization with alum-precipitated proteins (148), the
induction of the IgM response was CD40L-independent, whereas
switching was CD40L dependent [(49); data not shown]. Atypi-
cally, the EF IgM and IgG response in WT mice occurred in the
absence of a detectable GC response, which was not observed until
the infection was largely cleared (around day 35 in the described
model). Therefore, for at least 3 weeks, this model allows the assess-
ment of an EF response in the absence of a confounding influence
from GC.
The speed and extent of the EF response and the T-cell inde-
pendence of its induction had two major implications. First is that
there is a significant availability of antigen for B-cells to access,
despite the organism having an intracellular life-style and only
inducing a low grade bacteremia. Second, it suggests there is likely
to be a significant precursor B-cell pool that is enriched for anti-
gens present within this bacterium. Identifying which antigens
were targets of the atypical B-cell response was greatly aided by
the characterization of the prolonged antibody response to the
major porin proteins from S. Typhi OmpF and OmpC. Work by
Lopez-Macias, Isibasi and colleagues showed that immunization
of human beings and mice with purified, soluble porins induced
long-lived bactericidal antibody against typhoid (149, 150). These
proteins were good candidates as targets of the EF antibody
response in that they naturally share features of TI–II antigens
such as existing as oligomers and thereby containing repeating
epitopes (151). Immunization with purified porin proteins from
S. Typhimurium showed that these proteins induced a TI response
and induced protective antibody primarily through the presence
of an additional porin, OmpD, which is absent in S. Typhi (46).
Characterizing the peritoneal B-cell response to porin proteins and
FIGURE 2 |The development of antibody responses in mice after
Salmonella infection. After infection, there is a rapid induction of
extrafollicular responses, so that IgM and IgG plasma cells are readily
detectable by day 3. These events occur in the absence of germinal center
(GC) responses that are absent until infection has all but cleared.
MZ – marginal zone.
live S. Typhimurium showed that both antigens induced a B1b cell
response. In contrast, heat-killed bacteria or purified, monomeric
flagellin did not. Immunization with TLR grade LPS also induces
features of a B1b response, although it is unclear how much of
this is antigen-specific or induced through its mitogenic effects.
In responses to other Gram-negative bacteria, LPS may induce a
B1a response (152). A marker commonly used to help identify
B1b cells is CD11b. After infection of WT, but not T-cell-deficient
mice, the majority of B1b cells was not CD11b+. Thus, it is pos-
sible that examination of the response in WT mice using CD11b
may under-estimate the numbers of B1b cells, although other rea-
sons may help explain this, such as the maturity of the B1b cells
after infection or that additional B1 lineages are recruited to the
response.
This model allowed the investigation of other key questions
regarding B1b cells, one of which is whether multiple B1b anti-
gens exist within the same species. This was investigated using the
Vi antigen from S. Typhi. This antigen, in purified form, is used as
a vaccine against typhoid in human beings (146). Since S. Typhi
is a human pathogen with limited infectivity in non-primates, it
was necessary to examine the response in mice to S. Typhimurium
engineered to express Vi antigen and to purified Vi itself (81, 153).
This allowed a combined approach to be used where the response
to Vi in the context of the bacterium or after immunization with
the purified antigen could be examined. These experiments con-
firmed the TI nature of the response to Vi and showed that it
induced a B1b cell response. Furthermore, the antibody generated
by B1b chimeras was sufficient to provide protection against chal-
lenge with S. Typhimurium expressing Vi. Thus, the same species
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FIGURE 3 |The relative contribution of antibody from B1 and B2 cells.
Antibody provides a wall of protection against infection. Antibody to many
B1(b) antigens is also protective and suggests that a wide repertoire of
responses are not always necessary to protect against infection. Since
antibody to many antigens is not protective, it may be that antibody derived
from B1 cells provides greater protection in relative terms than that from
B2 cells, particularly follicular B-cells. In the context of this figure, the
mortar fills the gaps between the bricks, which provide the majority of
protective coverage.
of bacterium contains multiple B1b antigens, suggesting they may
be more widely distributed than was perhaps originally perceived
when the pioneering studies were being undertaken.
CONCLUSION
The evidence clearly shows that B1 cells play an important role
in providing antibody against infection. Between the B1 subsets,
B1b cells are most associated with providing responsive antibody
during natural infection or after vaccination. The targets of B1b
cell-derived antibody appear to have a disproportionate likeli-
hood of also being protective antigens and many of these antigens
are known to induce protective responses in human beings. This
strongly supports the concept that the B-cell receptor usage by B1b
cells is not random. Furthermore, the antigens recognized by B1b
cells are not limited to any one genus or Gram classification. The
detection of multiple protective B1b antigens in a single species
suggests that B1b antigens are widespread. Therefore, even allow-
ing for the incomplete understanding of B1 responses in human
beings examining B1b antibody responses in mice is likely to be a
rewarding avenue for identifying putative vaccine candidates.
From a personal perspective, there remain a number of unre-
solved questions regarding the contribution of antibody from and
the biology of B1 cells. How complete is our understanding of the
nature of selection of B1 cells? How can they be selectively enriched
to recognize protective antigens and epitopes? How widespread
are B1b cells in human beings? How great is the contribution of
antibody from B1b cells to protection after vaccination or nat-
ural infection compared to B2 cells and do B1b cells primarily
target bacteria and is this restricted to cell wall antigens? Thus, if
we think of the protection provided by antibody as a wall then
most of a wall is occupied by the bricks, with the gaps between
filled by mortar. If antibody to B1b antigens is sufficient to protect
against most infections, then the coverage offered by this would
be sufficient to protect against the majority of bacterial threats
(Figure 3). The remaining spaces would be filled by antibodies
derived from other B-cell subsets and contribute to protection
against antigens such as soluble toxins where there is no evidence
of any contribution of B1b cells. How does conjugating a B1b
antigen, such as pneumococcal polysaccharide to a typical pro-
tein carrier like CRM197, alter the responsiveness of B1b cells to
this antigen? Furthermore, how well can B1b cells switch? Experi-
ments using Salmonella show how closely the TI induction of the
response and the TD switching in the same response are coupled
and so we suspect they are two features of the same B-cell pop-
ulation. Is this really the case or are there two parallel responses
induced concurrently? Finally, can B1b cells take part in the GC
response? The expansion in the numbers and types of antigens
recognized by these cells, the models available, and the intensive
investigations underway in human beings make the coming years
an exciting time for this field and have implications for both basic
and applied immunology, microbiology, and vaccinology.
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